Table 2. . Comparison of dosing characteristics of liposomal amikacin for inhalation with other inhaled antibiotic drugs for treatment of Pseudomonas aeruginosa in cystic fibrosis.

Antibiotic	Drug class	Dosing and delivery
Liposomal amikacin for inhalation (LAI; Arikayce™)	Aminoglycoside	560 mg QD by nebulization with eFlow®
Tobramycin inhalation solution (TIS)	Aminoglycoside	300 mg/5 ml BID by nebulization with PARI LC Plus nebulizer
Tobramycin inhalation powder (TIP)	Aminoglycoside	112 mg BID by dry-powder inhaler with T-326 device
Nebulized concentrated tobramycin (NCT; T100; Vantobra)	Aminoglycoside	170 mg/1.7 ml BID by nebulization with TOLERO operated with eBase controller
Aztreonam solution for inhalation (AZLI; Cayston®)	Beta-lactam	75 mg TID by nebulization with eFlow
Colistimethate sodium (Colobreathe™)	Polymixin	1,662,500 IU inhalation powder, hard capsules. One capsule inhaled BID
Fosfomycin/tobramycin for inhalation (FTI)	Phosphoenolpyruvate synthetase inhibitor	80 mg/20 mg TID by nebulization with eFlow
Levofloxacin (Aeroquin™)	Fluoroquinolone	240 mg BID by nebulization with eFlow

BID: Twice daily; QD: Once a day; TID: Three-times daily; IU: International units.